How effective is Sectral for Arrhythmias? (a real world drug study)

Summary:

Overall ratings: 4/5
Long term ratings: 4.3/5

This is a phase IV clinical study of how effective Sectral (acebutolol hydrochloride) is for Arrhythmias and for what kind of people. The study is created by eHealthMe from 4 Sectral users and is updated continuously.

What is Sectral?

Sectral has active ingredients of acebutolol hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 3,548 Sectral users. Check the latest studies of Sectral.

What is Arrhythmias?

Arrhythmias (irregular heartbeat) is found to be associated with 2,761 drugs and 4,837 conditions by eHealthMe. Check the latest studies of Arrhythmias.


On Jun, 18, 2026

4 people are studied for taking Sectral in Arrhythmias

Overall effectiveness (number of people):

Does Sectral work for your Arrhythmias (overall)?

Long term (1+ years) effectiveness (number of people):

Does Sectral work for your Arrhythmias (long term)?

Sectral effectiveness for Arrhythmias (number of people):

Overall:
  • not at all: 0
  • somewhat: 0
  • moderate: 1
  • high: 2
  • very high: 1
Long Term:
  • not at all: 0
  • somewhat: 0
  • moderate: 0
  • high: 2
  • very high: 1

Gender of people who take Sectral for Arrhythmias *:

  • female: 75 %
  • male: 25 %

Age of people who take Sectral for Arrhythmias *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 25 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 25 %

Who find Sectral more effective for Arrhythmias?

Gender of people who take Sectral for Arrhythmias *:

  • female: 66.67 %
  • male: 33.33 %

Age of people who take Sectral for Arrhythmias *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 66.67 %
  • 60+: 33.33 %

* Approximation only. Some reports may have incomplete information.

Do you take Sectral?

- You can start a phase IV clinical trial to monitor Sectral safety and effectiveness.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Alternative drugs to, pros and cons of:

Treatments, associated drugs and conditions:

How the study uses the data?

The study is based on acebutolol hydrochloride (the active ingredients of Sectral) and Sectral (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: